Persistent Asset Partners Ltd
13F Reported Value
ⓘ$335.1M
incl. option notional
Equity Holdings
ⓘ$317.0M
Option Notional
ⓘ$18.2M
$2.1M puts / $16.1M calls
Holdings
818
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Persistent Asset Partners Ltd disclosed 818 positions worth $335.1M in its Form 13F-HR for Q2 2026 — $317.0M in common stock plus $18.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $INTC (INTEL CORP) at 7.6% of the equity portfolio, followed by $HOOD and $STM. During the quarter the fund opened 626 new positions and exited 131 — including a new stake in $HOOD and a full exit from $LITE. The portfolio is most concentrated in Technology (40.1% of disclosed assets). All figures are sourced directly from Persistent Asset Partners Ltd’s Form 13F-HR filing with the SEC under CIK 2056052.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 45.6#1,864
Quality
$24.2M173,113 sh - 82.1#16
Quality
$19.2M191,095 sh - —
Quality
$16.9M225,636 sh - 79.3
Quality
$13.3M75,502 sh - —
Quality
$8.9M9,265 sh - 71.3
Quality
$7.6M13,981 sh - —
Quality
$7.3M38,726 sh - 54.9
Quality
$7.1M27,783 sh - 54.9
Quality
$6.2M445,837 sh - —
Quality
$5.9M44,256 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| 45.6#1,864 | $24.2M | 173,113 | |
| 82.1#16 | $19.2M | 191,095 | |
| — | $16.9M | 225,636 | |
| 79.3 | $13.3M | 75,502 | |
| — | $8.9M | 9,265 | |
| 71.3 | $7.6M | 13,981 | |
| — | $7.3M | 38,726 | |
| 54.9 | $7.1M | 27,783 | |
| 54.9 | $6.2M | 445,837 | |
| — | $5.9M | 44,256 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Persistent Asset Partners Ltd's 818 positions.
Showing top 10 of 818 holdings.
Sector Allocation
Technology
$127.2M
Healthcare
$97.9M
Industrials
$30.9M
Financials
$24.6M
Materials
$18.1M
Consumer Discretionary
$7.1M
Energy
$3.6M
Communication Services
$3.1M
Top Holdings — Persistent Asset Partners Ltd (Q2 2026)
Top 150 of 818 disclosed positions (by reported value) from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | INTEL CORP | $24.2M | 7.6% | -37% | 45.6 | |
| 2 | Robinhood Markets, Inc. | $19.2M | 6.0% | NEW | 82.1 | |
| 3 | STMicroelectronics N.V. | $16.9M | 5.3% | NEW | — | |
| 4 | AMPHENOL CORP /DE/ | $13.3M | 4.2% | NEW | 79.3 | |
| 5 | Seagate Technology Holdings plc | $8.9M | 2.8% | NEW | — | |
| 6 | UNITED THERAPEUTICS Corp | $7.6M | 2.4% | +103% | 71.3 | |
| 7 | Revolution Medicines, Inc. | $7.3M | 2.3% | +49% | — | |
| 8 | Snowflake Inc. | $7.1M | 2.2% | NEW | 54.9 | |
| 9 | FORD MOTOR CO | $6.2M | 2.0% | NEW | 54.9 | |
| 10 | Abivax S.A. | $5.9M | 1.9% | +94% | — | |
| 11 | APPLIED MATERIALS INC /DE | $5.6M | 1.8% | NEW | 72.3 | |
| 12 | Cogent Biosciences, Inc. | $5.4M | 1.7% | +49% | — | |
| 13 | KLA CORP | $5.0M | 1.6% | NEW | 78.6 | |
| 14 | BIOMARIN PHARMACEUTICAL INC | $4.6M | 1.4% | +113% | 58.2 | |
| 15 | Viking Therapeutics, Inc. | $4.4M | 1.4% | -15% | — | |
| 16 | CADENCE DESIGN SYSTEMS INC | $4.2M | 1.3% | NEW | 72.6 | |
| 17 | LAM RESEARCH CORP | $3.8M | 1.2% | NEW | 79.4 | |
| 18 | SEMTECH CORP | $3.5M | 1.1% | -30% | 55.9 | |
| 19 | HONEYWELL INTERNATIONAL INC | $3.5M | 1.1% | NEW | 65 | |
| 20 | Honeywell Aerospace Inc. | $3.4M | 1.1% | NEW | — | |
| 21 | WESTERN DIGITAL CORP | $3.1M | 1.0% | NEW | 80.7 | |
| 22 | Sandisk Corp | $3.1M | 1.0% | -90% | 87.7 | |
| 23 | Edgewise Therapeutics, Inc. | $2.8M | 0.9% | +591% | — | |
| 24 | LITTELFUSE INC /DE | $2.7M | 0.8% | NEW | 51.6 | |
| 25 | CORNING INC /NY | $2.4M | 0.8% | -84% | 73.7 | |
| 26 | MICRON TECHNOLOGY INC | $2.4M | 0.8% | -88% | 86.2 | |
| 27 | Viking Therapeutics, Inc. | $2.3M | — | +86% | — | |
| 28 | ONTO INNOVATION INC. | $2.3M | 0.7% | NEW | 61.9 | |
| 29 | Kodiak Sciences Inc. | $2.2M | 0.7% | +9% | — | |
| 30 | TripAdvisor, Inc. | $2.2M | 0.7% | +58% | 40.8 | |
| 31 | PDD Holdings Inc. | $2.1M | 0.7% | +91% | — | |
| 32 | ADVANCED ENERGY INDUSTRIES INC | $2.1M | 0.7% | NEW | 61.7 | |
| 33 | NexGen Energy Ltd. | $2.1M | 0.7% | -5% | — | |
| 34 | ELDORADO GOLD CORP /FI | $2.1M | 0.7% | +28% | — | |
| 35 | ENTEGRIS INC | $2.1M | 0.7% | NEW | 58 | |
| 36 | Immunocore Holdings plc | $2.1M | 0.7% | +33% | — | |
| 37 | Abivax S.A. | $2.1M | — | +252% | — | |
| 38 | PRECIGEN, INC. | $2.0M | 0.6% | +2445% | 29.6 | |
| 39 | Bitdeer Technologies Group | $2.0M | 0.6% | +35% | — | |
| 40 | Nebius Group N.V. | $2.0M | 0.6% | -61% | — | |
| 41 | 4D Molecular Therapeutics, Inc. | $1.9M | 0.6% | NEW | 34.5 | |
| 42 | Amcor plc | $1.9M | 0.6% | +45% | — | |
| 43 | Navan, Inc. | $1.8M | 0.6% | NEW | 41.9 | |
| 44 | Arcus Biosciences, Inc. | $1.8M | 0.6% | -5% | 8.5 | |
| 45 | MKS INC | $1.6M | 0.5% | +588% | 61.2 | |
| 46 | CORCEPT THERAPEUTICS INC | $1.6M | — | +31% | 57.8 | |
| 47 | EXPAND ENERGY Corp | $1.5M | 0.5% | +31% | 80.8 | |
| 48 | Trekor Metals Ltd | $1.5M | 0.5% | -7% | — | |
| 49 | TORM plc | $1.5M | 0.5% | NEW | — | |
| 50 | JOHNSON & JOHNSON | $1.4M | 0.5% | -59% | 69 | |
| 51 | Hudbay Minerals Inc. | $1.4M | 0.4% | NEW | — | |
| 52 | CMB.TECH NV | $1.4M | 0.4% | -13% | — | |
| 53 | GOLAR LNG LTD | $1.3M | 0.4% | NEW | — | |
| 54 | Relay Therapeutics, Inc. | $1.3M | 0.4% | +332% | 19.5 | |
| 55 | NOVO NORDISK A S | $1.2M | 0.4% | +595% | — | |
| 56 | Equinox Gold Corp. | $1.2M | 0.4% | +3% | — | |
| 57 | DigitalOcean Holdings, Inc. | $1.2M | 0.4% | NEW | 67.2 | |
| 58 | SHOPIFY INC. | $1.1M | 0.4% | NEW | 64.9 | |
| 59 | Corvus Pharmaceuticals, Inc. | $1.1M | 0.3% | +21% | — | |
| 60 | SIMILARWEB LTD. | $1.1M | 0.3% | +0% | — | |
| 61 | Okeanis Eco Tankers Corp. | $1.1M | 0.3% | NEW | — | |
| 62 | Kymera Therapeutics, Inc. | $1.0M | — | NEW | 28.4 | |
| 63 | Indivior Pharmaceuticals, Inc. | $1.0M | 0.3% | +38% | 58.5 | |
| 64 | Centerra Gold Inc. | $1.0M | 0.3% | NEW | — | |
| 65 | Invesco Ltd. | $992,998 | 0.3% | NEW | — | |
| 66 | uniQure N.V. | $982,565 | — | -7% | — | |
| 67 | Zymeworks Inc. | $939,341 | 0.3% | +0% | 8.7 | |
| 68 | BioAge Labs, Inc. | $913,071 | 0.3% | +146% | 26.8 | |
| 69 | Taysha Gene Therapies, Inc. | $908,529 | 0.3% | NEW | 4.9 | |
| 70 | Vaxcyte, Inc. | $878,054 | 0.3% | +184% | — | |
| 71 | Coupang, Inc. | $869,611 | 0.3% | NEW | 50.6 | |
| 72 | SELLAS Life Sciences Group, Inc. | $852,895 | — | +34% | — | |
| 73 | Canadian Solar Inc. | $850,870 | 0.3% | +6% | — | |
| 74 | POWER SOLUTIONS INTERNATIONAL, INC. | $850,291 | 0.3% | +409% | 64.4 | |
| 75 | Monte Rosa Therapeutics, Inc. | $824,808 | 0.3% | -28% | 30.3 | |
| 76 | CRH PUBLIC LTD CO | $821,546 | 0.3% | -32% | — | |
| 77 | Qnity Electronics, Inc. | $791,074 | 0.3% | -5% | 68.4 | |
| 78 | Inventiva S.A. | $790,708 | 0.3% | +63% | — | |
| 79 | B2GOLD CORP | $780,957 | 0.3% | NEW | — | |
| 80 | Spyre Therapeutics, Inc. | $777,713 | 0.3% | +82% | — | |
| 81 | DORIAN LPG LTD. | $773,553 | 0.2% | NEW | — | |
| 82 | ASTRAZENECA PLC | $769,478 | 0.2% | +228% | — | |
| 83 | Nurix Therapeutics, Inc. | $751,405 | 0.2% | NEW | 6.4 | |
| 84 | Corbus Pharmaceuticals Holdings, Inc. | $721,500 | 0.2% | -31% | — | |
| 85 | Marvell Technology, Inc. | $721,192 | 0.2% | -84% | 76.5 | |
| 86 | Vera Therapeutics, Inc. | $707,372 | 0.2% | NEW | — | |
| 87 | FIRST SOLAR, INC. | $702,097 | 0.2% | -5% | 79.2 | |
| 88 | CAPRICOR THERAPEUTICS, INC. | $697,076 | — | +0% | 13.6 | |
| 89 | Oruka Therapeutics, Inc. | $674,279 | 0.2% | NEW | — | |
| 90 | Definium Therapeutics, Inc. | $648,118 | 0.2% | -13% | — | |
| 91 | Guardant Health, Inc. | $641,379 | 0.2% | +5% | 39 | |
| 92 | DARLING INGREDIENTS INC. | $632,538 | 0.2% | +23% | 63.5 | |
| 93 | PBF Energy Inc. | $631,727 | 0.2% | +112% | 50.5 | |
| 94 | Sanofi | $629,235 | 0.2% | +48% | — | |
| 95 | Bloom Energy Corp | $621,746 | 0.2% | +738% | 66.2 | |
| 96 | THERMO FISHER SCIENTIFIC INC. | $619,180 | 0.2% | +146% | 65.1 | |
| 97 | STRYKER CORP | $603,863 | 0.2% | +73% | 72.1 | |
| 98 | RELMADA THERAPEUTICS, INC. | $598,186 | 0.2% | +70% | — | |
| 99 | UNITEDHEALTH GROUP INC | $593,104 | 0.2% | NEW | 62.7 | |
| 100 | GeneDx Holdings Corp. | $587,301 | 0.2% | NEW | 35.4 | |
| 101 | Invesco Ltd. | $575,232 | 0.2% | NEW | — | |
| 102 | ArriVent BioPharma, Inc. | $546,599 | 0.2% | +94% | — | |
| 103 | Dianthus Therapeutics, Inc. /DE/ | $543,061 | 0.2% | -25% | 22.6 | |
| 104 | Contineum Therapeutics, Inc. | $541,477 | 0.2% | NEW | — | |
| 105 | REPLIGEN CORP | $532,389 | 0.2% | NEW | 58.4 | |
| 106 | NOKIA CORP | $523,259 | 0.2% | NEW | — | |
| 107 | NEKTAR THERAPEUTICS | $522,248 | 0.2% | +29% | 9.7 | |
| 108 | Summit Therapeutics Inc. | $519,509 | — | NEW | — | |
| 109 | Phathom Pharmaceuticals, Inc. | $517,143 | 0.2% | +78% | 40.9 | |
| 110 | Mirum Pharmaceuticals, Inc. | $515,576 | 0.2% | +23% | 35 | |
| 111 | Almonty Industries Inc. | $508,938 | 0.2% | NEW | — | |
| 112 | BICYCLE THERAPEUTICS PLC | $497,157 | 0.2% | -3% | — | |
| 113 | Alkermes plc. | $489,265 | 0.1% | -63% | — | |
| 114 | Fulgent Genetics, Inc. | $488,232 | 0.1% | NEW | 23.1 | |
| 115 | TENAX THERAPEUTICS, INC. | $481,328 | — | NEW | — | |
| 116 | Liquidia Corp | $478,779 | 0.1% | NEW | 78.3 | |
| 117 | Enliven Therapeutics, Inc. | $478,725 | 0.1% | +43% | — | |
| 118 | Trevi Therapeutics, Inc. | $477,459 | 0.1% | -8% | — | |
| 119 | Veradermics, Inc | $468,524 | 0.1% | -59% | — | |
| 120 | Viridian Therapeutics, Inc.\DE | $468,251 | 0.1% | NEW | 27.2 | |
| 121 | CYTOKINETICS INC | $455,426 | 0.1% | NEW | 28.1 | |
| 122 | Avalo Therapeutics, Inc. | $453,573 | 0.1% | +210% | 11.7 | |
| 123 | ALUMIS INC. | $443,667 | — | +101% | 7.1 | |
| 124 | NEWS CORP | $443,629 | 0.1% | -53% | 55.4 | |
| 125 | MACROGENICS INC | $440,614 | 0.1% | -37% | 39.6 | |
| 126 | ProQR Therapeutics N.V. | $439,804 | 0.1% | +413% | — | |
| 127 | Edwards Lifesciences Corp | $438,369 | 0.1% | -30% | 69.4 | |
| 128 | Lantheus Holdings, Inc. | $432,998 | 0.1% | +48% | 61.1 | |
| 129 | ABBOTT LABORATORIES | $432,830 | 0.1% | -30% | 65.5 | |
| 130 | Biohaven Ltd. | $424,166 | — | +0% | — | |
| 131 | Unicycive Therapeutics, Inc. | $422,874 | 0.1% | +236% | — | |
| 132 | SPRUCE BIOSCIENCES, INC. | $414,558 | 0.1% | +204% | — | |
| 133 | Anteris Technologies Global Corp. | $413,109 | 0.1% | -51% | — | |
| 134 | CAPRICOR THERAPEUTICS, INC. | $404,940 | — | -14% | 13.6 | |
| 135 | Replimune Group, Inc. | $396,972 | — | +241% | — | |
| 136 | Broadcom Inc. | $395,882 | 0.1% | NEW | 84.5 | |
| 137 | ARDELYX, INC. | $394,592 | 0.1% | NEW | 41.9 | |
| 138 | uniQure N.V. | $393,583 | 0.1% | +8% | — | |
| 139 | Alcoa Corp | $391,415 | 0.1% | NEW | 63.4 | |
| 140 | Roivant Sciences Ltd. | $389,998 | 0.1% | NEW | — | |
| 141 | Cue Biopharma, Inc. | $389,198 | 0.1% | -63% | 28.9 | |
| 142 | Mineralys Therapeutics, Inc. | $388,782 | 0.1% | -6% | — | |
| 143 | Forte Biosciences, Inc. | $388,089 | 0.1% | +171% | — | |
| 144 | Axsome Therapeutics, Inc. | $385,023 | 0.1% | NEW | 40.8 | |
| 145 | Erasca, Inc. | $376,897 | 0.1% | -27% | — | |
| 146 | — | PROTHENA CORP PLC - SHS | $372,999 | 0.1% | NEW | — |
| 147 | TELEPHONE & DATA SYSTEMS INC /DE/ | $368,175 | 0.1% | NEW | 42.3 | |
| 148 | Voyager Therapeutics, Inc. | $365,901 | 0.1% | -2% | 8.1 | |
| 149 | Cencora, Inc. | $356,555 | 0.1% | +4% | 61.1 | |
| 150 | Oculis Holding AG | $355,127 | 0.1% | NEW | — |
New Positions (626)
Exited Positions (131)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Persistent Asset Partners Ltd including:
Track Persistent Asset Partners Ltd's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Persistent Asset Partners Ltd and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Persistent Asset Partners Ltd
13F Pro is an AI hedge fund tracker and stock research platform. For Persistent Asset Partners Ltd (SEC CIK: 2056052), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Persistent Asset Partners Ltd's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.